Last updated: 2026-10-17 23:39:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Profound Medical Corp. (PROF) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $6.03, with a market capitalisation of $230.57M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.80 to $8.95. This page covers its latest market performance, valuation, price trends and company information.
$230.57M | |
$6.33 | |
$28.97 | |
$3.10 | |
$6.31 | |
112.69K | |
190.77K | |
-- | |
$8.95 | |
$4.80 | |
-- | |
-- |
Profound Medical Corp. (PROF) last closed at $6.31 as of 2026-10-16 23:31:00, unchanged from the previous close of $6.31.
During the latest regular trading session, PROF traded between $3.10 and $28.97, with a volume of 112.69K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Profound Medical Corp. (PROF) moved from $6.91 to $6.03, representing a decline of 12.81% ($0.88).
The stock traded between $6.01 and $7.40 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 663.57 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 29.5%
PROF is currently trading at $6.03, placing it 29.5% of the way from its 52-week low of $4.80 to its 52-week high of $8.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 162 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Profound Medical Corp. (PROF) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.